Funding profile · Healthcare AI, Southeast Asia
Bot MD
One announced round of US$5 million in five years, no SEC filings by design, a new investor in 2025 with nothing disclosed behind it, and a seed number three outlets reported three different ways.
$5.0MSeries A led by Monk’s Hill Ventures, announced February 2021
$5.7MTotal across two rounds per Tracxn; LeadIQ says $6.6M
0SEC Form D filings, and none expected of a Singapore issuer
50+Healthcare institutions using the platform, investor stated Sep 2025
Data as of September 23, 2026. Company-reported figures are labeled.
Rounds at a glance
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Aug 2018 | Seed, out of Y Combinator | $700,000 reported | Y Combinator and angel investors | Trade press |
| Oct 2018 | Seed, cumulative to date | About US$1.59M reported | Y Combinator and angels including Steve Blank | TODAY |
| Jan 2019 | Seed, cumulative to date | USD 1.6 million reported | Floodgate and Steve Blank named | Hive Life |
| Dec 2020 to Feb 2021 | Series A | US$5,000,000 | Monk’s Hill (lead), SeaX Ventures, XA Network, SGInnovate, Yoh-Chie Lu, Jean-Luc Butel, Steve Blank | Press and database |
| Sep 2025 | Undisclosed | Not disclosed | Verge HealthTech Fund | Investor memo |
| Cumulative | Two rounds on record | $5.7M (Tracxn) or $6.6M (LeadIQ) | Ten institutional and three angel investors per Tracxn | Sources disagree |
What the filings show
Bot MD · public records search · run September 23, 2026
- Form D filings
- None
- EDGAR mentions
- None, including vehicles named for the company
- FDA 510(k) or PMA
- None
- Registered trials
- None
- NIH or NSF awards
- None attributable
- PubMed
- No papers under the company or product name
- Why
- Regulation D covers offerings made into the United States. Bot MD is a Singapore issuer raising from Singapore and Southeast Asian investors, so silence in EDGAR is expected, not a signal. Singapore share allotments are lodged with ACRA.
Reading the filings
- The absence of a Form D is structural, not evasive.A records pull returned zero Form D notices and zero EDGAR filings mentioning the company. A US filing trail would only appear if securities had been sold into the United States under Regulation D, and nothing suggests they were.
- The seed number moved three times in five months.MobiHealthNews reported $700,000 in August 2018. TODAY reported about US$1.59 million in October 2018. Hive Life reported USD 1.6 million in January 2019 and named Floodgate, which neither of the others did. The first two figures are roughly $890,000 apart in eleven weeks. Either the round kept closing, or the first report counted only the accelerator cheque.
- Announcement and database date differ by six weeks.Crunchbase records the Series A announced date as December 22, 2020. The press ran on February 2 and 3, 2021, and Tracxn dates the round February 2, 2021. That matters only when reading growth claims tied to a calendar year: the user numbers in the February coverage describe activity through 2020.
- A new investor appeared in 2025 with no round attached.Verge HealthTech Fund published an investment memo on September 8, 2025 and lists Bot MD as an active portfolio company. No amount, round name or close date has been published, and no third party total has moved since. Five years between the Series A and a disclosed follow-on points to a quiet extension, revenue funding the growth, or both.
- The commercial databases are unreliable here.Tracxn places the company in Palo Alto and lists the founders as Dorothea Koh plus a second entry it cannot resolve. Owler places it in Anaheim, California. The company site, all Series A coverage and the WHO listing place it in Singapore with two named founders. The same databases supply the $5.7M and $6.6M totals, so treat both as indicative.
- Revenue is an estimate standing in for a disclosure.GetLatka publishes $2.3M for 2024, labels it an estimate, and on the same page shows funding as $0. Headcount is equally unsettled: 15 in 2021, 15 again in 2024, 40 by October 2024 per a founder interview, 30 per Tracxn in July 2026.
Commercial signals
| Signal | Detail | Source type |
|---|---|---|
| Named customers | In Singapore: NUHS, National University Cancer Institute, Tan Tock Seng, Changi General, Singapore General, Parkway Radiology, Alexandra Hospital, KK Women’s and Children’s. In the Philippines: National Kidney and Transplant Institute, St. Luke’s, Philippine General Hospital. | Independent |
| Largest account | Siloam Hospitals Group, 41 hospitals and 66 clinics, more than five million patients a year. Memorandum of understanding signed March 2023 covering outcome measures over WhatsApp. | Independent |
| Channel | Indonesian Medical Association, more than 200,000 doctor members, assistant embedded on its website in Bahasa Indonesia and English, March 2023. | Independent |
| Government backing | SGInnovate, described in press coverage as Singapore government-owned, since the Series A. No Enterprise Singapore or Startup SG grant found. | Independent |
| Certification | ISO 27001, stated in a NUS case study prepared with the CEO. No certificate number or registrar published. | Company-informed |
| Clinical evidence | One BMJ Open retrospective review of the platform in 2020, which does not name the company. Nothing indexed in PubMed under the company name. | Public record |
| Regulatory | No HSA medical device registration found. The products are described as scheduling, education, reminders and data collection, outside the diagnosis and treatment boundary in HSA guidance. | Not found |
| Headcount | 15 (2021 and 2024), 40 (Oct 2024, founder interview), 30 (Tracxn, Jul 2026). | Sources disagree |
What to watch
- A named and sized round behind the September 2025 Verge HealthTech investment.
- An ACRA share allotment record, where a Singapore raise becomes visible without a press release.
- Any disclosed revenue or customer count to replace the third party estimates.
- An HSA classification if the agents move from collecting data to triaging it.
- Published outcomes from the Siloam and KK Women’s and Children’s programmes.
The Bot MD story on Healthcare DiscoveryHealthcare Discovery
Related companies
Sources
- Public recordSEC, FDA, NIH, NSF, trial and PubMed records pull returning no hits
- Public recordRemote monitoring of marginalised populations affected by COVID-19
- Public recordDigital Health and software medical device guidance
- IndependentBot MD raises $5 million for expansion into Asian markets
- IndependentBot MD lands $5M for its AI clinical assistant
- IndependentBot MD raises US$5m led by Monk’s Hill Ventures
- Independent‘Medical Google’ for doctors?, with the US$1.59M seed figure
- IndependentAn App to Help Doctors Save Lives, with the USD 1.6 million figure
- IndependentBot MD powers data collection in Indonesia
- InvestorWhy We Invested in Bot MD, and the portfolio listing
- DatabaseSeries A round record, announced Dec 22, 2020
- EstimateFunding, headcount and revenue estimates
- Case studyBot MD Care case study, with the ISO 27001 statement
- CompanyBot MD site, about page and testimonials
Compiled from public records and published reports as of September 23, 2026. No SEC filing exists for this company, the expected result for a Singapore issuer raising outside the United States; amounts come from press reports and commercial databases and may be incomplete. Healthcare Venture Capital Fund holds no position in Bot MD. This page is not an offer to sell or a recommendation to buy any security.